Back to Treatments

Treatment

Rituximab with Hyper-CVAD/MA

1
Conditions
50
Trials
5,000
Participants
25%
Average Safety

Condition Evidence

Burkitt lymphoma

50 trials · 5,000 participants

87% effectiveness · 25% safety
Rituximab with Hyper-CVAD/MA | DFDA